German pharma has 10 HIV treatments in clinical trials
Tackling HIV/AIDS remains a top priority for German pharma. 33.3 million people worldwide are infected with HIV, with 2.6 million infected in 2009, according to the latest UNAIDS report. Almost 2 million people died of AIDS last year.
While the global rate of new HIV infections has declined by almost a fifth in a decade, Eastern Europe remains a trouble spot, with infections trebling in the last 10 years, while southern Africa still has the most new infections. Western Europe saw 8,500 deaths, with 431 in Germany. 820,000 western Europeans are HIV-positive.
Cornelia Yzer, general manager of the German research-based pharmaceutical association VFA, noted this week that “10 new treatments for HIV are currently being tested on patients, and many more are being investigated in laboratories”.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze